Chr. Hansen Holding A/S (0MR6.L)
| Previous close | 449.94 |
| Open | 448.60 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 448.10 - 457.30 |
| 52-week range | 448.10 - 457.30 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 594.536M |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | 0.09 |
| EPS (TTM) | 47.85 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Novozymes and Chr. Hansen receive binding tax ruling that the proposed merger can be completed as a tax-exempt merger
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. JANUARY 24, 2023 On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen propose to combine and create a leading global biosolutions partner by way of a statutory merger of the two companies (the
- Globe Newswire
Chr. Hansen Holding A/S Interim Report Q1 2022/23
January 12, 2023 – Company announcement no. 1 Solid Q1 supports the outlook for 2022/23 Statement by CEO Mauricio Graber: “The solid results for Q1 show the strength of our business model. Organic growth reached 10%, driven by both volume and pricing initiatives and EBIT b.s.i. increased by 17% supported by the organic growth and exchange rates, leading to an EBIT margin b.s.i. of 24.7%. In light of the Q1 performance we maintain our underlying target for the year but update the outlook to refle
- Globe Newswire
Novozymes and Chr. Hansen to combine and create a leading global biosolutions partner
DECEMBER 12, 2022 – ANNOUNCEMENT NO. 13 Novozymes and Chr. Hansen have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. The combination is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large. Please see attachment. CONTACT INFORMATION Novozymes:Investor RelationsTobias Cornelius Björklund+45 3077 8682tobb@novozymes.comChr. Hansen:Investor R
